Distinct activating in EGFR and activation of associated signaling pathways is a well-established finding in upto 20% of adenocarcinoma located in the lung [6,7] and tyrosine-kinase inhibitors (TKI) directed against the EGFR have entered clinical practice. Here, EGFR is linked to adenocarcinoma.